Join
Live feed
·
PRReleasevia Quantisnow
Jupiter Neurosciences Inc. logo

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

ByQuantisnow·Wall Street's wire, on your screen.
JUNS· Jupiter Neurosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JUNS (Jupiter Neurosciences Inc.) and more on Quantisnow.